Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:sec><jats:title>Objective</jats:title><jats:p>To determine the microRNA (miR) signature in ankylosing spondylitis (AS) T helper (Th)17 cells.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Interleukin (IL)-17A-producing CD4+ T cells from patients with AS and healthy controls were FACS-sorted for miR sequencing and qPCR validation. miR-10b function was determined by miR mimic expression followed by cytokine measurement, transcriptome analysis, qPCR and luciferase assays.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>AS Th17 cells exhibited a miR signature characterised by upregulation of miR-155-5p, miR-210-3p and miR-10b. miR-10b has not been described previously in Th17 cells and was selected for further characterisation. miR-10b is transiently induced in in vitro differentiated Th17 cells. Transcriptome, qPCR and luciferase assays suggest that MAP3K7 is targeted by miR-10b. Both miR-10b overexpression and MAP3K7 silencing inhibited production of IL-17A by both total CD4 and differentiating Th17 cells.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>AS Th17 cells have a specific miR signature and upregulate miR-10b in vitro. Our data suggest that miR-10b is upregulated by proinflammatory cytokines and may act as a feedback loop to suppress IL-17A by targeting MAP3K7. miR-10b is a potential therapeutic candidate to suppress pathogenic Th17 cell function in patients with AS.</jats:p></jats:sec>

Original publication

DOI

10.1136/annrheumdis-2016-210175

Type

Journal article

Journal

Annals of the Rheumatic Diseases

Publisher

BMJ

Publication Date

03/2017

Volume

76

Pages

620 - 625